Literature DB >> 6421529

Ceiling respiratory depression by dezocine.

A Romagnoli, A S Keats.   

Abstract

Dezocine in equianalgesic intravenous doses depressed respiratory response to CO2 breathing of six healthy subjects to approximately the same degree as morphine but with a more rapid onset and higher peak depression. The depression was dose related up to 30 mg/70 kg but was not increased by an additional 10 mg/70 kg dose. Its duration of effect was approximately the same as that of morphine. Respiratory depression by dezocine was promptly and almost completely antagonized by 0.4 mg naloxone, but antagonism lasted less than 1 hr. Healthy subjects found dezocine less pleasant than morphine and after large doses reported sensations suggestive of psychotomimetic effects. A ceiling effect for respiratory depression has now been demonstrated for three agonist-antagonist analgesics: nalorphine, nalbuphine, and dezocine. It is not yet clear to what extent this is a general characteristic of agonist-antagonist analgesics.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6421529     DOI: 10.1038/clpt.1984.45

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J J O'Brien; P Benfield
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

2.  Subjective and behavioral responses to intravenous fentanyl in healthy volunteers.

Authors:  J P Zacny; J L Lichtor; J G Zaragoza; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Dezocine as a potent analgesic: overview of its pharmacological characterization.

Authors:  Rong-Rong Ye; Shuang Jiang; Xu Xu; Yan Lu; Yu-Jun Wang; Jing-Gen Liu
Journal:  Acta Pharmacol Sin       Date:  2021-11-04       Impact factor: 7.169

4.  Dezocine Has the Potential to Regulate the Clinical and Biological Features of Tumors.

Authors:  Xudong Hu; Bing Luo; Lei Qiu; Shaosen Chen; Qing Wu; Qingbiao Chen; Xingqing Liu; Chen Ling; Shuping Deng; Manjuan Yuan; Peicun Hu
Journal:  Drug Des Devel Ther       Date:  2022-04-20       Impact factor: 4.319

5.  Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers.

Authors:  J P Zacny; J L Lichtor; W Binstock; D W Coalson; T Cutter; D C Flemming; B Glosten
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 6.  Adverse effects of opioid agonists and agonist-antagonists in anaesthesia.

Authors:  T A Bowdle
Journal:  Drug Saf       Date:  1998-09       Impact factor: 5.606

7.  National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018.

Authors:  Honghao Shi; Xianwen Chen; Xueli Liu; He Zhu; Fei Yu; Carolina Oi Lam Ung; Wai Sin Chan; Hao Hu; Sheng Han
Journal:  J Pharm Policy Pract       Date:  2021-05-25

8.  Dezocine exhibits antihypersensitivity activities in neuropathy through spinal μ-opioid receptor activation and norepinephrine reuptake inhibition.

Authors:  Yong-Xiang Wang; Xiao-Fang Mao; Teng-Fei Li; Nian Gong; Ma-Zhong Zhang
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

9.  Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist.

Authors:  Yu-Hua Wang; Jing-Rui Chai; Xue-Jun Xu; Ru-Feng Ye; Gui-Ying Zan; George Yun-Kun Liu; Jian-Dong Long; Yan Ma; Xiang Huang; Zhi-Chao Xiao; Hu Dong; Yu-Jun Wang
Journal:  Sci Rep       Date:  2018-09-20       Impact factor: 4.379

10.  Dezocine regulates the malignant potential and aerobic glycolysis of liver cancer targeting Akt1/GSK-3β pathway.

Authors:  Zi-Wen Zhong; Wen-Chang Zhou; Xing-Feng Sun; Qi-Chao Wu; Wan-Kun Chen; Chang-Hong Miao
Journal:  Ann Transl Med       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.